These webinar slides explore the benchmark practices for rapid progression from First-in-Human to large-scale commercial manufacture for micro-dosing API. Xcelodose®-based systems are an industry standard for rapid and accurate micro-dosing and an integral part of accelerated pathways to first-in-human studies. Utilization of the Xcelodose® technology can increase the speed to the clinic and quickly assess new compounds while remaining cost-conscious.  Upon successful clinical studies, scale up to large-scale manufacture has previously been a limitation. Micro-dosing with the innovative Harro Höfliger Modu-C Mid Speed Encapsulator, these limitations are no longer an impediment to scale-up and commercialization.
Content Type: Presentation (on-demand)
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center